Sanofi’s Regeneron fix requires extra shot of M&A
SNY•Sanofi struck a deal with Regeneron worth up to $7 billion to develop four drugs, including $1 billion upfront. The deal comes as Dupixent faces patent expiry in 2031, and the article says Sanofi will need more deals to restock its pipeline.
1. Four-drug partnership
Sanofi and Regeneron expanded their partnership to develop four new drugs in a deal worth up to $7 billion. Sanofi will pay $1 billion upfront, with further payments tied to development, regulatory and commercial milestones.
2. Pipeline and patent expiry
The deal also settles litigation between the partners and addresses investor concerns about Dupixent, their eczema drug, which is set to lose patent protection in 2031. The article says Sanofi will need more deals to restock its pipeline and notes that new CEO Belen Garijo has the firepower to pursue them.
